CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...

The use of CT scans is moving beyond a simple diagnostic tool for non–cystic fibrosis bronchiectasis to become a practical ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Please provide your email address to receive an email when new articles are posted on . Tobramycin inhalation solution was effective in lowering bacterial density and positively influenced quality of ...

BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...